Danaher Co. (NYSE:DHR) Stock Holdings Lessened by Arthur M. Cohen & Associates LLC

Arthur M. Cohen & Associates LLC reduced its stake in Danaher Co. (NYSE:DHR - Free Report) by 0.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 212,639 shares of the conglomerate's stock after selling 1,623 shares during the period. Danaher accounts for 8.7% of Arthur M. Cohen & Associates LLC's portfolio, making the stock its 2nd largest position. Arthur M. Cohen & Associates LLC's holdings in Danaher were worth $48,811,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Brooklyn Investment Group increased its stake in shares of Danaher by 7.7% during the fourth quarter. Brooklyn Investment Group now owns 5,289 shares of the conglomerate's stock valued at $1,214,000 after purchasing an additional 378 shares in the last quarter. Sax Wealth Advisors LLC increased its position in Danaher by 83.7% during the 4th quarter. Sax Wealth Advisors LLC now owns 3,260 shares of the conglomerate's stock valued at $748,000 after buying an additional 1,485 shares in the last quarter. Merit Financial Group LLC raised its stake in Danaher by 14.3% during the fourth quarter. Merit Financial Group LLC now owns 10,050 shares of the conglomerate's stock valued at $2,307,000 after buying an additional 1,260 shares during the last quarter. CNB Bank boosted its holdings in Danaher by 3.6% in the fourth quarter. CNB Bank now owns 3,777 shares of the conglomerate's stock worth $867,000 after acquiring an additional 130 shares in the last quarter. Finally, Avanza Fonder AB purchased a new stake in shares of Danaher in the fourth quarter worth $10,990,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Danaher Stock Performance

Shares of NYSE:DHR traded down $3.49 during mid-day trading on Friday, reaching $238.41. 3,044,734 shares of the company traded hands, compared to its average volume of 2,640,177. Danaher Co. has a 52 week low of $222.53 and a 52 week high of $281.70. The firm has a market cap of $172.20 billion, a PE ratio of 45.50, a PEG ratio of 4.23 and a beta of 0.83. The company's 50 day moving average price is $234.85 and its 200-day moving average price is $253.42. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01.

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.57 by $0.14. The firm had revenue of $5.80 billion during the quarter, compared to analysts' expectations of $5.59 billion. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The company's revenue for the quarter was up 3.1% compared to the same quarter last year. During the same period in the prior year, the company posted $2.02 earnings per share. On average, equities analysts expect that Danaher Co. will post 7.49 EPS for the current fiscal year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be paid a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.45%. The ex-dividend date is Friday, December 27th. Danaher's dividend payout ratio (DPR) is 20.61%.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on DHR shares. Wolfe Research upgraded shares of Danaher from a "peer perform" rating to an "outperform" rating and set a $285.00 price target on the stock in a research note on Thursday, October 31st. StockNews.com cut shares of Danaher from a "buy" rating to a "hold" rating in a report on Saturday, December 14th. Robert W. Baird decreased their price objective on shares of Danaher from $278.00 to $277.00 and set an "outperform" rating for the company in a report on Wednesday, October 23rd. Citigroup cut their target price on Danaher from $305.00 to $285.00 and set a "buy" rating on the stock in a research note on Monday, January 6th. Finally, Barclays decreased their price target on Danaher from $285.00 to $275.00 and set an "equal weight" rating for the company in a research note on Wednesday, October 23rd. Six research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to MarketBeat.com, Danaher currently has an average rating of "Moderate Buy" and an average price target of $286.80.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.